With the recruitment of Pernilla Fagergren, CombiGene strengthens the company further for the clinical studies in the epilepsy project CG01
In 2021, CombiGene’s epilepsy project CG01 will focus on the final preclinical studies. In parallel, the company will intensify preparations for studies in humans, known as clinical studies, which are scheduled to begin in 2022. CombiGene has now recruited Pernilla Fagergren to the positon as Clinical Project Manager, which means that Pernilla will be responsible for preparing and running the first clinical study.
Pernilla Fagergren has a broad experience from academia and industry. She holds a PhD at Karolinska Institutet in Stockholm and has conducted research at Mount Sinai School of Medicine in New York, USA. Pernilla comes most recently from Merck AB where she worked as a medical advisor and manager in neurology. Prior to that, she worked as a researcher with early pharmaceutical projects at Karo Bio AB. Her expertise covers key areas such as drug development, project management and neuropharmacology. Pernilla also has extensive experience in national and international collaboration with physicians and leading medical opinion leaders. Pernilla will report to CombiGene’s Chief Research and Development Officer Karin Agerman.
“I am incredibly pleased that we have succeeded in recruiting Pernilla Fagergren to CombiGene”, says Karin Agerman. “Pernilla has just the deep knowledge of drug development and clinical studies that we are looking for. Her experience from international work in both industry and academia will be crucial as we step up the preparation work for the first study in human within our epilepsy project CG01.”
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.